Subtitle: Market Intelligence, Preclinical Progress, and High-Purity Reagents for Allergy & Immunology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MILR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MILR1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MILR1 Products |
| Gene Delivery | MILR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MILR1 Products |
| Benchmark Ab | Anti-MILR1 (Research Grade Control) Recombinant positive control for assay development. |
View MILR1 Products |
| Validator | MILR1 siRNA Set For knockdown verification. |
View MILR1 Products |
| Related Target A | FCER1A High-affinity IgE receptor alpha subunit; synergistic target for mast cell regulation. |
View FCER1A Products |
| Related Target B | PTPN6 (SHP-1) Downstream ITIM signaling phosphatase recruited by MILR1. |
View PTPN6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Conformation (Two Ig-like C2 domains) | HEK293 Expressed (Native Glycosylation) ensuring proper folding of extracellular domains. |
| Functional Cellular Screening | Premade Lentivirus for rapid, stable expression in mast cell/basophil models. |
| Lack of Reliable Controls | Sequence Verified recombinant benchmark antibodies included for assay standardization. |
| False Positives in Binding Assays | High Purity (>95%) antigens, Endotoxin Controlled to prevent non-specific immune activation. |
Live MILR1 R&D Tracker
Market data and preclinical research change daily. Access the latest global pipeline status directly:
Global Preclinical Landscape & Future Outlook
MILR1 (Mast cell immunoglobulin-like receptor 1, also known as Allergin-1) is an emerging inhibitory receptor primarily expressed on mast cells and basophils. It features two extracellular Ig-like C2-type domains and an intracellular ITIM (Immunoreceptor tyrosine-based inhibitory motif). Upon activation, MILR1 recruits SHP-1 and SHP-2 to suppress IgE-mediated anaphylaxis and allergic responses.
Currently, MILR1 therapeutics are in the preclinical discovery phase. The therapeutic hypothesis centers on developing agonistic agents that can trigger MILR1's inhibitory signaling to suppress mast cell degranulation. As research into severe allergies, asthma, and chronic spontaneous urticaria progresses, the future outlook (hypothesized over the next 3-5 years) points toward the exploration of agonistic monoclonal antibodies and novel bispecific formats designed to co-engage MILR1 and activating receptors (such as FcεRI).
Hypothetical Modality & Indication Snapshot
| Modality | Representative Players | Key Indications (Hypothesized) | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic mAb | Preclinical / Academic Consortia | Asthma, Allergic Rhinitis | Agonism Validation (Need high-purity ECD-Fc) |
| Bispecific (e.g., MILR1 x FcεRI) | Early Discovery Biotech | Severe Anaphylaxis | Co-engagement Assay (Need Lentivirus for stable cell lines) |
| Gene Therapy / RNAi | Preclinical Researchers | Chronic Urticaria | Target Knockdown (Need Validated siRNA) |